Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

Stock Information for Gritstone bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Gritstone bio Inc.

Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update
Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure
Investors Have The Opportunity To Lead The Gritstone bio, Inc. Securities Fraud Lawsuit With The Schall Law Firm
Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
GRITSTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Gritstone bio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Investors Are Invited To Take The Lead In The Gritstone Bio Inc Securities Fraud Case With The Schall Law Firm
DEADLINE ALERT for GRTS, PATH, and NKE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
GRTS Investors Have The Opportunity To Lead Gritstone Bio Inc Securities Fraud Lawsuit With The Schall Law Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.